6-K: Gsk Receives Us Fda Breakthrough Therapy Designation for Its B7-H3-Targeted Antibody-Drug Conjugate in Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
6-K: Gsk Receives Us Fda Breakthrough Therapy Designation for Its B7-H3-Targeted Antibody-Drug Conjugate in Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
Gsk的B7-H3靶向抗體藥物偶聯物獲得美國FDA突破性療法認定，用於治療復發或難治性廣泛期小細胞肺癌
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間